Physician profile
Ashley E Vanord
NPI 1134469653
$1,672.87
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $782 · 2022: $891.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.65 | 2021-2022 | |
| Ucb, INC. | $647.55 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $76.81 | 2021-2022 | |
| Pfizer INC. | $57.83 | 2021-2022 | |
| Lilly USA, LLC | $44.24 | 2021-2022 | |
| Leo Pharma INC. | $39.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.23 | 2022 | |
| Incyte Corporation | $16.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.10 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.81 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Vanord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.